The Times Congo mine deaths raise safety questions at Glencore: Glencore was facing fresh questions about its safety record yesterday after an accident at a mine in the Democratic
ImmuPharma PLC (LSE:IMM) the specialist drug discovery and development company, confirmed to DirectorsTalk that it has received a TR-1 by Aviva plc and its subsidiaries confirming its increased holding in ImmuPharma
UK Broker Upgrades / Downgrades Code Company Broker Recomm. From Recomm. To Price From Price To Upgrades ADM Admiral Group Plc Nomura Neutral Buy 1630 2325 BARC Barclays
Allergy Therapeutics plc (AIM:AGY), the fully integrated specialty pharmaceutical company specialising in allergy vaccines, has given DirectorsTalk its unaudited interim results for the six months ended 31 December 2015.
1: NOTIFICATION OF MAJOR INTEREST IN SHARES 1. Identity of the issuer or the underlyingissuer of existing shares to which votingrights are attached: Immupharmaplc 2. Reason for the notification (please tick
OptiBiotix Health plc (LON:OPTI) presented at the 2nd Microbiome R&D and Business Collaboration Congress: Asia, part of Global Engage’s worldwide microbiome series. The conference was attended by over 180 leading
Evgen Pharma’s Dr Stephen Franklin discusses obtaining the required approval to start Phase II clinical trial on SFX-01 in this exclusive interview with DirectorsTalk
UK Broker Upgrades / Downgrades Code Company Broker Recomm. From Recomm. To Price From Price To Upgrades ADM Admiral Group Plc Deutsche Bank Hold Hold 1515 1750 AGK
Motif Bio’s Dr Graham Lumsden discusses the first patient dosed in the Iclaprim Phase III trials in this exclusive interview with DirectorsTalk
The Times Global fears as markets lose faith in central banks: The global economy is heading for a storm as faith in policymakers dwindles, according to a stark warning
© 2025 – DirectorsTalk. All rights reserved. Reproduction in whole or in part, in any form or medium without express written permission is prohibited.
